Despite study design biases and technical artifacts affecting single cancer biomarker history, they find applications in diagnosis (e.g., Bence-Jones protein in myeloma), prognosis (e.g., hCG in testicular cancer), and predicting treatment outcomes (e.g., ALK gene rearrangements guiding treatment in lung cancer). Here, ALK is linked to plasma cell myeloma.